

# TOP 50

## APAC CELL & GENE THERAPY COMPANIES



The Asia-Pacific region is rapidly emerging as a global leader in cell and gene therapy (CGT), with companies across China, Japan, South Korea, India, Singapore, Australia, and New Zealand advancing therapies from discovery to commercialization.

This report highlights the Top 50 CGT companies in APAC, showcasing their therapy modalities, clinical stages, and oncology or regenerative medicine focus.

CGT World Asia 2026 brings this community together, offering a unique platform to connect with decision-makers, explore collaborations, and accelerate therapies from lab to patient.

Rank	Company	Country	Modality	Clinical Stage	Focus
1	 <b>LEGEND</b> BIOTECH	China	CAR-T	Approved / P3	Multiple myeloma
2	 <b>药明巨诺</b> JW Therapeutics	China	CAR-T	Approved / P2-3	Hematologic cancers
3	 <b>FOSUNKite</b> 福森药业	China	CAR-T	Approved	Lymphoma
4	 <b>CARSGEN</b> THERAPEUTICS	China	CAR-T	P2	Solid + heme
5	 <b>IASO</b> BIOTHERAPEUTICS	China	CAR-T	P2-3	MM / autoimmune
6	 <b>GRACELL</b> 亘喜生物	China	CAR-T	P1-2	B-cell / autoimmune
7	 <b>BELIEF</b> BIOMED	China	AAV gene therapy	P3	Hemophilia
8	 <b>Neurophth</b> 纽福斯	China	AAV gene therapy	P1-2	Ophthalmology
9	 <b>CANbridge</b> 北海康成	China	Gene therapy	P1-2	Rare disease
10	 <b>NUIDAGENE</b> THERAPEUTICS	China	CRISPR / gene therapy	P1-2	Multi-indication
11	 <b>赛百诺</b> SIBIONO	China	Gene therapy	Approved	Oncology
12	 <b>SPH</b> 上海医药 <b>甘戎生物</b> SHANGHAI PHARMA GANWAY BIO	China	Oncolytic virus	Approved	Oncology
13	 <b>ImmVira</b> 亦诺微医药	China	Oncolytic virus	P1-2	Solid tumors

14		China	CAR-T	P3	Solid tumors
15		China	Gene therapy	P3	Ophthalmology
16		Japan	AAV gene therapy	PI-2	Rare disease
17		Japan	CAR-T	Approved / P2-3	Oncology
18		Japan	iPSC therapy	Approved	Parkinson's
19		Japan	MSC therapy	Approved	Brain injury
20		Korea	NK cell therapy	P2-3	Oncology
21		China	CRISPR / cell therapy	PI-2	Oncology
22		China	Cell therapy	PI-2	Oncology
23		China	Gene therapy	Clinical	Genetic disease
24		China	AAV gene therapy	PI-2	Ophthalmology
25		China	Gene therapy	PI-2	CNS
26		China	AAV gene therapy	PI-2	Rare disease
27		China	Oncolytic virus	PI-2	Oncology
28		China	Allogeneic CAR-T	PI-2	Oncology
29		China	Cell therapy	PI-2	Oncology
30		China	Gene therapy	PI-2	Hemophilia
31		China	Gene therapy	PI-2	ALS
32		Korea	CRISPR	PI-2	Genetic disease
33		Korea	DNA gene therapy	P3	Neuropathy

34		Korea	MSC therapy	Approved	OA
35		Australia	MSC therapy	Approved / P3	GVHD
36		China	CAR-T	PI-2	B-cell
37		China	CAR-T / TCR-T	PI-2	Oncology
38		China	In vivo CAR-T	PI	Oncology
39		China	Gene editing	PI-2	Rare disease
40		Taiwan	NK cell therapy	PI	Solid tumors
41		Taiwan	Stem cell	P2	Neuro
42		Japan	DNA gene therapy	Approved	CLI
43		Japan	Stem cell / iPSC	P2	ARDS
44		Japan	iPSC therapy	PI-2	Heart failure
45		Korea	RNA therapy	PI-2	Oncology
46		Korea	Stem cell	P2	Neuro
47		Korea	Oncolytic virus	P2-3	Oncology
48		Australia	NK / CAR-T	PI-2	Oncology
49		Australia	CAR-T	PI-2	Solid tumors
50		India	CAR-T	Approved / P2	B-cell malignancies

APAC's CGT landscape is dynamic and rapidly evolving, with companies driving breakthroughs in CAR-T, gene therapy, stem cell therapies, and other advanced modalities.

CGT World Asia 2026 connects you directly with these innovators, providing opportunities to form partnerships, discover new technologies, and stay ahead of industry trends.

This is the platform where Asia's CGT ecosystem meets, collaborates, and grows.



# CELL & GENE THERAPY WORLD ASIA 2026

30 June - 1 July 2026  
Sands Expo & Convention Centre, Singapore

Co-located with:



500+ Attendees

150+ Organizations

50+ Expert Speakers

## APAC's Premier CGT Congress - Uniting Leaders, Innovation, and Quality

#CGTAsia2026: driving breakthroughs in research, clinical applications, and manufacturing, while addressing Asia's unique challenges.

 [Visit Our Website](#)